Related by context. Frequent words. (Click for all words.) 86 Secondary endpoints included 76 Secondary endpoints 65 evaluable 65 secondary endpoint 64 patients evaluable 63 annualized relapse 63 RECIST criteria 63 cytogenetic response 63 demonstrated statistically significant 63 surrogate endpoint 63 #mg/day [001] 62 confidence interval CI 62 mg QD 62 achieved statistical significance 62 p = #.# [004] 62 statistically significant improvement 62 plus prednisone 62 % CI #.#-#.# [003] 61 biochemical recurrence 61 P = .# 61 estimated glomerular filtration 61 placebo p = 61 prespecified 61 primary efficacy endpoint 61 free survival PFS 61 Main Outcome Measures 61 HRQoL 61 pharmacodynamic effects 61 complete cytogenetic 61 secondary endpoints 60 secondary efficacy endpoints 60 ADAS cog 60 histologic 60 chlorambucil 60 plus methotrexate 60 PANSS 60 p = #.# [002] 60 erythrocyte sedimentation rate 60 evaluable patients 60 confidence interval #.#-#.# 59 plus dexamethasone 59 pharmacokinetic profiles 59 CI -#.# 59 mucosal healing 59 mg kg dose 59 Pharmacokinetic 59 TAXUS p value 59 pharmacodynamic 59 Cmax 59 tumor lysis syndrome 59 Unified Parkinson Disease 59 serum concentrations 59 univariate 59 CI #.#-#.# [002] 59 irbesartan 58 % CI #.#-#.# [007] 58 μg kg 58 composite endpoint 58 lymphopenia 58 mcg kg 58 mg BID 58 MADRS 58 laboratory abnormalities 58 ≥ 58 hypoglycemic events 58 seroprotection 58 plus ribavirin 58 HbA1C 58 RECIST 58 placebo p 58 ACR# response 58 QTc 58 statistically significant p = 58 primary endpoint 58 univariate analysis 58 apolipoprotein B 58 Natalizumab 57 XIENCE V vs. 57 COPD exacerbations 57 n = 57 intravesical 57 gout flares 57 statistically significant p 57 % CI #.#-#.# [006] 57 Negative Syndrome 57 sensitivity specificity 57 HRQOL 57 p = 57 fraction LVEF 57 fasting insulin 57 cardiovascular morbidity 57 undetectable HCV RNA 57 hypomagnesemia 57 mRCC 57 morbidity mortality 57 Postoperative 57 distant metastasis 57 elotuzumab 57 thromboembolic events 57 pharmacodynamics 56 acute GVHD